In this study, we utilized a conditioning regimen with fludarabine and myeloablative dose i.v. BU (12.8 mg/kg) (FluBU) in 36 adult patients (median age: 44 years, range: 18-61) with myeloid or lymphoid malignancies at standard risk (n ¼ 10) or high risk of relapse (n ¼ 26), who received an allogeneic hematopoietic SCT (HSCT) from HLA-matched related (n ¼ 16) or unrelated (n ¼ 20) donors. The source of hematopoietic stem cells was peripheral blood in 28 and marrow in 8 cases. Rabbitantithymocyte globulin at 7 mg/kg was utilized in 21 patients. Acute GVHD grade II-IV was observed in 19% of the patients (grade III-IV in 14% of patients) and chronic GVHD in 11 of 30 evaluable patients (37%). At median follow-up of 737 days (range: 152-1737) for alive patients, overall survival rates in standard-and high-risk patients were 80 and 35%, respectively, and event-free survival rates were 70 and 31%, respectively. TRM was 10% in standard-risk and 19% in high-risk patients. Post transplant relapse was observed in 20% standard-risk and in 46% high-risk patients. FluBU conditioning regimen is associated with a limited hematologic and extrahematologic toxicity and with an antitumor activity comparable to other standard myeloablative regimens.
Introduction
The treatment of hematological malignancies, which are considered at high risk due to biological, or cytogenetic, or molecular characteristics associated with poor outcome, or to relapse or persisting disease after chemotherapy, is still very challenging because of the limited survival of these patients. [1] [2] [3] [4] Allogeneic hematopoietic SCT (HSCT) has been exploited in this setting with the goal of inducing a graft-versus-tumor immune effect to target tumor cells, which can not be eradicated by chemo/radiotherapy.
However, the choice of the conditioning regimen before allogeneic HSCT may have an impact on the overall outcome of the transplant. In fact, more intensive (fully myeloablative) regimens can destroy tumor cells effectively, but can also cause greater morbidity and mortality due to toxicity, particularly in older patients. 5 On the other hand, reduced-intensity conditioning (partially myeloablative or nonmyeloablative) regimens cause limited transplant-related mortality and allow allogeneic HSCT to be performed more safely in elderly patients, but may have less antitumor effect per se. 6 In patients with hematological malignancies at high risk of relapse, a greater dose of chemo/radiotherapy is likely to result in a greater antitumor effect and possibly improved survival. 7 Therefore, age of patients, presence of comorbidities and disease status are among the principal factors generally leading physicians' choice of conditioning regimen in allogeneic HSCT.
Nonhematopoietic toxicity associated with standard myeloablative regimens such as those with CY combined with oral BU or TBI remains a cause of mortality in elderly patients. Recently, fludarabine has been combined with myeloablative doses of BU (FluBU), [8] [9] [10] demonstrating a lower rate of complications. In addition, the use of i.v. BU has significantly reduced the toxicity that had been previously observed with this compound, 8, 10 particularly veno-occlusive disorder. 11 We have recently observed that in PBSC transplants the FluBU causes hematological and extrahematological toxicities comparable to those observed utilizing a reducedintensity conditioning regimen, such as fludarabine/ melphalan. 12 In this study, we analyzed the clinical outcome of patients with hematological malignancies at standard or high-risk patients, who were transplanted after receiving FluBU as conditioning regimen. The results suggest that the regimen with myeloablative i.v. BU and fludarabine causes low TRM and can be successfully utilized also in high-risk patients, although leukemia patients with active disease still have a high rate of relapse, as with any other conditioning regimen.
Patients and methods

Patients
Thirty-six consecutive patients with hematological malignancies who received an allogeneic peripheral blood (n ¼ 28) or BM (n ¼ 8) HSCT conditioned with FluBU were evaluated in this study. An informed consent was signed before transplant and the transplants were performed according to the protocol approved by the University of Illinois at Chicago Institutional Review Board. Patients' median age was 44 years (range: 18-61) and their clinical characteristics are shown in Table 1 . Criteria for receiving FluBU as conditioning regimen included age p60 years, not having a diagnosis of myeloma or myelofibrosis (MF) in chronic phase, and not having received an autologous SCT within the previous 2 years. Of the 36 patients, 26 (72%) were considered at high risk due to AML in relapse (n ¼ 12), ALL in relapse (n ¼ 2), ALL in CR1 with high blast count at diagnosis (n ¼ 3), myelodysplastic syndrome with monosomy 7 (n ¼ 1), non-Hodgkin's lymphoma in relapse (n ¼ 2) or in CR2 (n ¼ 2), MF in leukemia transformation (n ¼ 1), or CML in accelerated phase (n ¼ 3). The median time from diagnosis to transplant was 12 months.
Donors
Of the 36 patients, 19 patients received a transplant from an unrelated donor and 17 patients were transplanted from related donors. HLA typing, in related donors, was performed by serology for class I and by low-resolution molecular testing for HLA-DRB1, whereas high-resolution molecular testing was performed for class I (A, B and C) and class II (HLA-DRB1) loci in unrelated transplants. All but two patients received an HLA-matched graft, whereas one patient received an HLA-2 alleles unrelated-mismatched graft and one patient received one antigenmismatched graft. Donor characteristics are shown in Table 2 . Donors who donated PBSC received recombinant human G-CSF (filgrastim) 10 mg/kg subcutaneously per day for 5 days before PBSC collection by leukapharesis. As expected, higher numbers of CD34 cells were infused in the PBSC group as compared to the group of patients transplanted with BM cells (Table 2) .
Transplantation
Patients initially received a dose of fludarabine of 30 (n ¼ 12) or 40 (n ¼ 24) mg/m 2 /day i.v. for 4 days (from day À9 to day À6), followed by BU 3.2 mg/kg. A single dose i.v./day for 4 days (day À5 to day À2), as reported previously.
12 GVHD prophylaxis consisted of standard MTX (on day 1 at 15 mg/m 2 , and on days 3, 6 and 11 at 10 mg/m 2 ) and tacrolimus (started on day À2). Tacrolimus levels were maintained between 5 and 15 ng/ml until day þ 180 unless GVHD or recurrence of disease occurred. A total of 21 patients including 19 patients receiving a transplant from unrelated donors and 2 patients with CML receiving a transplant from related donors, 13, 14 received thymoglobulin (rabbit antithymocyte globulin (ATG), Genzyme Inc., Cambridge, MA, USA) at 7 mg/kg total dose as additional GVHD prophylaxis on day À3 to day À1. Myeloid growth factors were not used in the peritransplant setting. Darbopoetin-alpha (Aranesp) was used in early phases after transplant in one Jehovah's witness patient.
Criteria for engraftment, toxicity and GVHD Initial neutrophil engraftment was defined as the first of 3 consecutive days with absolute neutrophil count equal to or more than 0.5 Â 10 9 /l. Initial platelet engraftment was defined as the first of 3 consecutive days with a platelet count of 20 Â 10 9 /l or more without transfusion support. Failure to engraft by day þ 30 was considered primary graft failure, whereas secondary graft failure was defined as initial engraftment followed by loss of graft function without recurrent malignancy. Post transplant donor chimerism was assessed by means of DNA microsatellite analysis as described previously. 15 Acute and chronic GVHD were graded according to standard criteria. 16, 17 Statistical analysis Statistical analyses were performed by means of w 2 -test. Survival estimates were obtained using the Kaplan-Meier method and differences were analyzed by log-rank test. 
Results
Engraftment
The results on the engraftment in this study (n ¼ 36 patients) include those on 18 patients that were previously compared to patients transplanted with a different conditioning regimen 12. Engraftment was achieved in all but two patients, who did not recover a platelet number 420 Â 10 9 /l, secondary to early leukemia relapse in the first patient and lethal infection before engraftment in the second patient. The overall median time to absolute neutrophil count (40.5 Â 10 9 /l) was 15 days (range: 10-27) and platelet count (420 Â 10 9 /l) was 13 days (range: 0-42) in the PBSC group and 23 days (range: 15-35) and 24 days (range: 17-49), respectively, in BM transplants. Interestingly, five patients never dropped their platelet count below 20 Â 10 9 /l. Of these patients, three had CML-CP, one AML in CR and one non-Hodgkin's lymphoma-CR2. Median chimerism on day 30 was 100% in both groups.
GVHD
Acute GVHD grade II-IV was observed in seven patients (19%) and grade III-IV was observed in five patients (all grade III). Of the seven patients, two developed acute GVHD grade III (skin and liver) after the withdrawal of immunosuppression due to relapse and another patient developed acute GVHD grade II after donor lymphocyte infusion 1 year after transplant. Chronic GVHD was observed in 11 of 30 (37%) evaluable patients, as shown in Table 3 . In patients at high risk, acute (grade II-IV) and chronic GVHD occurred in 18 and 43%, respectively. Of the patients at high risk who relapsed, only 3 of 12 had GVHD (acute GVHD grade III and extensive chronic GVHD on third-line immunosuppressive therapy, respectively) at the time of relapse.
Survival
At a median follow-up of 737 days (range: 152-1737) for patients who are alive, the overall survival (OS) was 47%. In standard-risk patients, the OS and event-free survival (EFS) were 80 and 70%, respectively, while in high-risk patients they were 35 and 31%, respectively ( Table 4) . As expected, patients at high risk had a lower OS and EFS than patients at standard risk (P ¼ 0.01 and P ¼ 0.03, respectively) and Kaplan-Meier curves with estimated OS and EFS in these groups of patients are shown in Figure 1b .
Fourteen patients (86% with active acute leukemia) relapsed at a median time of 70 days (range: 30-328). As expected, relapse rate was higher in high-risk (46%) as compared to standard-risk (20%) patients. Mortality due to early relapse occurred in 12 of 26 patients at high risk and 0 of 10 patients at standard risk. Mortality due to transplant-related complications occurred in five patients at high risk, who died from bacterial (n ¼ 4) or fungal (n ¼ 1) infections, and two patients at standard risk, who died from a bacterial infection and pulmonary embolism, respectively.
Survival in recipients of PBSC
We have previously shown that FluBU causes limited hematological and extrahematological toxicity in recipients of PBSC.
12. In our study, 8 of 36 patients received allogeneic marrow cells, mainly from unrelated donors, whereas 28 patients received PBSC. We retrospectively analyzed differences in the outcome of these two groups of patients. Of 28 patients who received PBSC, 20 were at high risk, whereas of 8 patients receiving marrow grafts, 6 were at high risk. PBSC patients had a trend toward an increased OS compared to BM recipients (P ¼ 0.1) ( Table 4) and among patients at high risk, those who received PBSC had a prolonged OS and EFS (40 and 40%, respectively) compared with those at high risk who received marrow grafts (17 and 17%, respectively; P ¼ 0.2). The difference was not significant likely due to the limited number of patients.
Discussion
In this study, we show that a conditioning regimen with fludarabine and i.v. BU at 12.8 mg/kg has limited toxicity and can be successfully utilized also in patients with highrisk hematological malignancies undergoing an allogeneic HSCT from related or unrelated donors.
Therapeutic options for these patients are limited due to a very high rate of relapse and/or resistance after different lines of radio/chemotherapy. 1,2,4,18 Allogeneic SCT, using TBI-based 19, 20 or chemotherapy-based myeloablative [21] [22] [23] regimens has the potential of curing many of these patients by means of a graft-versus tumor activity. Nevertheless, its effect can be hampered by drug-associated toxicities, infections or GVHD, particularly in adult patients. FluBU regimen in allo-HSCT for high-risk patients S Chunduri et al Different reduced-intensity conditioning regimens have been developed combining fludarabine with either lowdose TBI or chemotherapy [24] [25] [26] and have been also utilized in patients at high risk of relapse with the purpose of decreasing the TRM. The use of i.v. BU has decreased the toxicity of this drug, previously available only for oral administration likely because of a more stable concentration in the blood over the time of treatment. [8] [9] [10] The combination of fludarabine and myeloablative doses of BU has been proven as effective as CY and BU in patients with active disease, while a reduced dose of BU resulted ineffective in this patient population. 27 It is not yet clear, however, which dose of fludarabine is optimal in combination with BU. Russell et al.
8 utilized high-dose fludarabine (250 mg/m 2 ) and i.v. BU in 70 patients, and the projected risk of relapse in their study was 66% in the AML high-risk patients (n ¼ 36) and 18% in the other patients. This study also utilized ATG in all the transplants independently of related or unrelated donors. In another study, an intermediate dose of fludarabine (160 mg/m 2 ) was combined with i.v. BU, mostly in patients with AML 4CR1 or myelodysplastic syndrome, and showed an OS and an EFS of 65 and 52%, respectively, at 1 year. 10 Finally, a lower dose of fludarabine (120 mg/m 2 ) was combined with targeted doses of oral BU in patients with myelodysplastic syndrome (approximately 50% at high risk) and showed an OS of 42% and EFS of 35% at 18 months of follow-up. 9 In our study, we initially utilized a lower dose of fludarabine and then we increased it to an intermediate dose according to de Lima et al., 10 although no major differences in toxicity or outcome were observed. The OS was 80% in standard-risk patients and 35% in high-risk patients at over 2 years of follow-up. In our study, we also confirmed that the administration of i.v. BU in a single daily dose is safe as it did not cause any severe extrahematologic toxicity, such as veno-occlusive disease. The use of ATG in our study, mostly in unrelated transplant, has likely allowed us to limit the rate of severe acute GVHD. The beneficial use of ATG in related and unrelated donors has been recently supported also by others. 28, 29 In addition, fludarabine and i.v. BU did not result in high TRM in our experience as well as in other studies using a similar conditioning regimen. [8] [9] [10] Our findings suggest that the use of FluBU is a strategy to limit the toxicity previously observed with standard myeloablative conditioning regimens, while maintaining a full dose of the myeloablative agent. Overall, different results in high-risk patients may indeed depend on the intensity of the conditioning regimen, but these differences are likely due to the selection of patients with active disease, particularly acute leukemia, as opposed to patients with poor prognosis due to biologic characteristics but with stable disease or in remission. Patients with relapsed/ resistant-acute leukemia should be probably re-induced before transplant due to the limited success of this procedure in this setting. Instead, we observed good responses in patients with high-risk acute leukemia in CR and in patients with non-Hodgkin's lymphoma, who had been resistant or relapsed after conventional chemotherapy. Because of the limited number of patients, we were not able to assess whether PBSC or BM grafts resulted in better outcome in high-risk patients conditioned with FluBU, although a trend for better results was noticed with PBSC. FluBU regimen in allo-HSCT for high-risk patients S Chunduri et al
